Tacrolimus Administration for Organ Transplant Rejection Prophylaxis

Dosing and Monitoring Recommendations

The American Association for the Study of Liver Diseases recommends lower tacrolimus trough levels of 6-10 ng/mL during the first month followed by 4-8 ng/mL thereafter when combined with short-course corticosteroids, which improves renal function without increasing rejection rates in liver transplant patients 1
For renal-sparing combination regimens with basiliximab and/or MMF/azathioprine in liver transplant patients, target even lower trough levels of 4-7 ng/mL during the first month, followed by 3-5 ng/mL 1, 2
Beyond the first year post-transplant, most patients can be maintained on tacrolimus levels of 4-6 ng/mL with monotherapy or lower if combined with other immunosuppressants 1, 2

Administer tacrolimus capsules consistently either with or without food, as food can decrease absorption by 37% with a 77% decrease in maximum plasma concentration 3
Rigorous monitoring of tacrolimus trough levels is essential given the narrow therapeutic window and high inter-patient variability in pharmacokinetics 3, 4
Monitor serum creatinine, potassium, glucose, renal function, and hepatic function regularly to detect tacrolimus-induced abnormalities 5
Obtain baseline and ongoing complete blood counts, liver function tests, and blood pressure measurements 3

Monitor tacrolimus trough levels every other day during the immediate post-operative period until target levels are reached 4
Monitor tacrolimus trough levels daily for the first 7 days or until hospital discharge 4
Monitor tacrolimus trough levels 2-3 times per week for weeks 2-4 4
Monitor tacrolimus trough levels weekly for months 2 and 3 4
Monitor tacrolimus trough levels every 2 weeks for months 4-6 4
Monitor tacrolimus trough levels monthly for months 7-12 4
Monitor tacrolimus trough levels every 2-3 months thereafter 4

Use basiliximab and MMF or azathioprine to allow for a 5-day delay in the introduction of tacrolimus in patients at risk of post-transplant renal dysfunction 1, 2

Prophylaxis against Pneumocystis jiroveci should be implemented with tacrolimus use 3
Consider antifungal prophylaxis in patients receiving steroids for treatment of neurotoxicity 5

Monitor for donor-specific antibodies in combination with liver enzymes and non-invasive tests to identify patients at risk of subclinical rejection 1, 2
Many long-term survivors can maintain normal liver tests with tacrolimus levels substantially lower than initial targets, but the benefits must be weighed against the risk of subclinical rejection 1, 2
Conversion to CNI-free everolimus-based regimens can be achieved in more than 50% of patients beyond the first year 1, 2